Internal medicine (Tokyo, Japan) · 2008
Preventive effect of sulfamethoxasole-trimethoprim on Pneumocystis jiroveci pneumonia in patients with interstitial pneumonia.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Enomoto Tatsuji, Azuma Arata, Matsumoto Aki, Nei Takahito, Fujita Kazue, Hattori Kumiko, Saito Yoshinobu, Abe Shinji, Usuki Jiro, Kudoh Shoji
Аннотация
BACKGROUND: Pneumocystis jiroveci pneumonia (PCP) is a potentially fatal complication in interstitial pneumonia patients receiving glucocorticoid therapy. Prophylaxis of PCP during glucocorticoid therapy is an important issue in the treatment of interstitial pneumonia.
OBJECTIVE: We evaluated the prophylactic effect of sulfamethoxasole-trimethoprim (TMP-SMX) in interstitial pneumonia patients receiving glucocorticoids.
METHODS: We retrospectively analyzed 74 interstitial pneumonia patients who received glucocorticoid therapy.
RESULTS: Seven of the 74 patients developed PCP. At the time of diagnosis of PCP, the mean duration of glucocorticoid therapy was 71 days and the mean daily dose of prednisolone was 37 mg. Among the 7 patients, the circulating CD4+ lymphocyte count was 370 /microl on average and it was over 200 /microl in 3 cases. The PCP patients showed a significant reduction of the lymphocyte count at 4 weeks after initiation of steroid therapy. None of the patients who received prophylactic TMP-SMX therapy developed PCP even if the CD4+ lymphocyte count was less than 200 /microl.
CONCLUSION: Interstitial pneumonia patients receiving glucocorticoid therapy can benefit from TMP-SMX prophylaxis against PCP. Development of PCP cannot be ruled out in patients with a CD4+ lymphocyte count of greater than 200 /microl.
OBJECTIVE: We evaluated the prophylactic effect of sulfamethoxasole-trimethoprim (TMP-SMX) in interstitial pneumonia patients receiving glucocorticoids.
METHODS: We retrospectively analyzed 74 interstitial pneumonia patients who received glucocorticoid therapy.
RESULTS: Seven of the 74 patients developed PCP. At the time of diagnosis of PCP, the mean duration of glucocorticoid therapy was 71 days and the mean daily dose of prednisolone was 37 mg. Among the 7 patients, the circulating CD4+ lymphocyte count was 370 /microl on average and it was over 200 /microl in 3 cases. The PCP patients showed a significant reduction of the lymphocyte count at 4 weeks after initiation of steroid therapy. None of the patients who received prophylactic TMP-SMX therapy developed PCP even if the CD4+ lymphocyte count was less than 200 /microl.
CONCLUSION: Interstitial pneumonia patients receiving glucocorticoid therapy can benefit from TMP-SMX prophylaxis against PCP. Development of PCP cannot be ruled out in patients with a CD4+ lymphocyte count of greater than 200 /microl.
Предметные рубрики MeSH
AdultAgedAged, 80 and overAnti-Infective AgentsAntibiotic ProphylaxisCD4 Lymphocyte CountFemaleGlucocorticoidsHumansLung Diseases, InterstitialMaleMiddle AgedPneumocystis cariniiPneumonia, PneumocystisPrednisoloneRadiographyRetrospective StudiesTreatment OutcomeTrimethoprim, Sulfamethoxazole Drug Combination